<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00236249</url>
  </required_header>
  <id_info>
    <org_study_id>P041008</org_study_id>
    <nct_id>NCT00236249</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Intravenous Lidocaine After Colorectal Surgery: LIDOREHAB</brief_title>
  <official_title>Evaluation of Lidocaine Continuous Intravenous Administration for Postoperative Recovery After Colorectal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - H么pitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to check if lidocaine intravenous administration during surgery&#xD;
      and 24 hours after surgery, associated with standardised management of the patient, helps to&#xD;
      accelerate recovery and to improve the quality of recovery, after surgery for colic or rectal&#xD;
      neoplasms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the purposes of postoperative care is to shorten the duration of recovery, in order to&#xD;
      reduce the complications and to improve the quality of life. After abdominal surgery, two&#xD;
      factors can be modified: early mobilisation, thanks to optimal pain control, and return to a&#xD;
      normal feeding, permitted by transit recovery. Opioids, which are usually used for pain&#xD;
      control, delay the intestinal transit and can be responsible for side effects like&#xD;
      drowsiness, nausea, urine retention.&#xD;
&#xD;
      Lidocaine is a local anaesthetic, which means that it can stop the pain if it is&#xD;
      administrated around the nerves. It can also be used intravenously. In this way, it is&#xD;
      supposed to decrease opioid consumption, accelerate intestinal transit and even decrease&#xD;
      inflammation. Side effects of lidocaine appear at higher plasma concentrations than those&#xD;
      considered in the study.&#xD;
&#xD;
      After randomisation, the patient will receive either intravenous lidocaine during the surgery&#xD;
      and 24 hours after the surgery, or physiological serum (like placebo). Every patient will&#xD;
      dispose of patient-controlled-analgesia with morphine and of a standardised care management.&#xD;
      Data will be collected concerning pain level, morphine consumption, psychomotor performances,&#xD;
      duration of ileus, speed of activity recovery, quality of recovery, and side effects.&#xD;
      Biological evaluation of lidocaine concentration and inflammation will also be done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Readiness for discharge, checked twice a day</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain every 4 hours the first day after surgery, then twice a day</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption: dose of titration, then twice a day</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of transit recovery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical rehabilitation score daily</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor test daily until reaching of preoperative values</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery score at 1st, 3rd, and 6th day</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction score at discharge</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological inflammation the day before the surgery, then at 1st, 3rd, and 6th day</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lidocaine concentration at the end of surgery and 24 hours forward</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical side effects twice a day</measure>
  </secondary_outcome>
  <enrollment type="Actual">110</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Colorectal neoplasm&#xD;
&#xD;
          -  Radical surgery&#xD;
&#xD;
          -  Median incision&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) score equal to or up to 3&#xD;
&#xD;
          -  Unwilling or unable to use patient-controlled analgesia (PCA)&#xD;
&#xD;
          -  Chronic consumption of opioids&#xD;
&#xD;
          -  Chronic drug or alcohol abuse&#xD;
&#xD;
          -  Chronic pain&#xD;
&#xD;
          -  Unable to read or write text&#xD;
&#xD;
          -  Inflammatory disease of intestinal tract&#xD;
&#xD;
          -  Allergy to morphine&#xD;
&#xD;
          -  Allergy to lidocaine&#xD;
&#xD;
          -  Severe atrioventricular conduction dysfunction without stimulator&#xD;
&#xD;
          -  Porphyry&#xD;
&#xD;
          -  Uncontrolled epilepsy&#xD;
&#xD;
          -  History of malign hyperthermia&#xD;
&#xD;
          -  Severe cardiac failure&#xD;
&#xD;
          -  Hepatic failure&#xD;
&#xD;
          -  Myasthenia&#xD;
&#xD;
          -  Treatment with beta blockers, antiarrhythmic calcium blockers, sultopride,&#xD;
             nonselective monoamine oxidase inhibitor (MAOI)&#xD;
&#xD;
          -  Locoregional anaesthesia planned&#xD;
&#xD;
          -  Associated surgery concerning liver, pancreas, or gall bladder&#xD;
&#xD;
          -  Laparoscopic surgery&#xD;
&#xD;
          -  Severe psychiatric pathology&#xD;
&#xD;
          -  Refusal of the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Jolly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - H么pitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H么pital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>October 10, 2005</study_first_submitted>
  <study_first_submitted_qc>October 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>February 17, 2011</last_update_submitted>
  <last_update_submitted_qc>February 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Myriem CARRIER</name_title>
    <organization>Department of Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Double blind method</keyword>
  <keyword>Prospective study</keyword>
  <keyword>Lidocaine/administration and dosage/therapeutic use</keyword>
  <keyword>Anaesthetics local/administration and dosage</keyword>
  <keyword>Opioids/administration and dosage</keyword>
  <keyword>Pain, postoperative</keyword>
  <keyword>Perioperative care</keyword>
  <keyword>Postoperative care</keyword>
  <keyword>Analgesia, Patient-controlled</keyword>
  <keyword>Length of stay</keyword>
  <keyword>Survival analysis</keyword>
  <keyword>Patient satisfaction</keyword>
  <keyword>Surgery</keyword>
  <keyword>Middle age</keyword>
  <keyword>Adult</keyword>
  <keyword>Aged</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

